Mr. Ed Mathers has served as a Partner at NEA, a private venture capital firm focusing on technology and healthcare investments since August 2008. Mr. Mathers became a member of Mirna’s board of directors in October 2012. He also serves on the board of directors of Envisia Therapeutics, Inc., a biopharmaceutical company; Liquidia Technologies, a biotechnology company; Ra Pharmaceuticals, a biotechnology company; and Lumos Pharma, a biotechnology company. Previously Mr. Mathers served as Executive Vice President, Corporate Development and Venture, at MedImmune, Inc. and led its venture capital subsidiary, MedImmune Ventures, Inc. Before joining MedImmune, he was Vice President, Marketing and Corporate Licensing and Acquisitions at Inhale Therapeutic Systems. Previously, Mr. Mathers spent 15 years at Glaxo Wellcome, Inc., where he held various sales and marketing positions.